arrow
T

Toshiyuki Sumi

Hakodate Goryoukaku Hospital
H指数:19
被引数:1,530

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regimen selection for combined immunotherapy in non-small cell lung cancer with PD-L1 < 1%: a multicenter, retrospective study from Japan (SPIRAL-LT1)

PD-L1<1%的非小细胞肺癌联合免疫治疗方案选择:一项来自日本的多中心回顾性研究(SPIRAL-LT1)

2026-10-160
OAAI
Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)

老年晚期非小细胞肺癌患者一线免疫治疗后治疗方案(NEJ057)

2026-10-030
PRE
Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer

程序性死亡配体1表达对表皮生长因子受体突变非小细胞肺癌患者一线奥希替尼早期进展和长期反应的时间依赖性影响

2026-09-210
OA
Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes

阿法替尼与奥希替尼治疗 uncommon EGFR 突变的非小细胞肺癌:真实世界结果

2026-05-310
OAAI
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病(合并与不合并CTLA-4方案)在PD-L1 < 1 %的非小细胞肺癌患者中的研究:一项多中心、回顾性研究

2025-09-260
PRE
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗:一项在日本进行的多中心回顾性观察队列研究(REAL-SPEED)。

2025-06-160
OA
Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study

纳武利尤单抗和伊匹木单抗联合或未联合化疗治疗不可切除非小细胞肺癌的疗效与安全性:一项多中心回顾性观察研究

2025-01-031
OA
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)

Durvalumab在EGFR突变型非小细胞肺癌经化疗放疗后的应用:一项真实世界研究(HOT2101)

2024-12-010
PRE
Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study

EGFR突变非小细胞肺癌中阿法替尼(AFA)序贯奥希替尼(OSI)治疗:基于Gio-Tag Japan多中心前瞻性观察研究的初始阿法替尼剂量探索性分析

2024-12-010
PRE
Cisplatin (CDDP) plus Etoposide (ETP) plus Durvalumab (DUR) vs. Carboplatin (CBDCA) plus ETP plus Atezolizumab (ATZ): Propensity score matching (PSM) real-world data (RWD) on CDDP-fit extensive disease (ED)-small cell lung cancer (SCLC)

顺铂(CDDP)联合依托泊苷(ETP)联合度鲁木单抗(DUR)与卡铂(CBDCA)联合依托泊苷(ETP)联合阿替利珠单抗(ATZ):基于倾向性评分匹配(PSM)的真实世界数据(RWD),针对CDDP适合的广泛期(extensive disease, ED)小细胞肺癌(SCLC)。

2024-12-010
PRE
Esophagomediastinal fistula during durvalumab plus tremelimumab with chemotherapy in angiotensin-converting enzyme 2-positive non-small cell lung cancer: a case report

durvalumab联合tremelimumab联合化疗治疗血管紧张素转换酶2阳性非小细胞肺癌期间食管纵隔瘘: 一例病例报告

2024-10-010
OAAI
Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057

肺癌免疫预后指数(LIPI)作为指导老年非小细胞肺癌(NSCLC)患者(Pts)在免疫治疗中添加化疗的依据:NEJ057

2024-09-010
PRE